We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

The global Liquid Biopsy Market, valued at US$5.9 billion in 2023, is forecasted to grow at a robust CAGR of 11.9%, reaching ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

In addition to the coverage in NSCLC, Signatera is also covered by Medicare for adjuvant and recurrence monitoring in colorectal cancer, muscle-invasive bladder cancer, breast cancer, and ovarian ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price boosted by research analysts at The Goldman Sachs Group ...

The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...